A5100459422- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Retinal Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Intraocular Surgery and Lenses
- Cardiomyopathy and Myosin Studies
- Retinal and Optic Conditions
- Endometriosis Research and Treatment
- Glaucoma and retinal disorders
- Retinal Imaging and Analysis
- Cardiovascular Health and Risk Factors
- Uterine Myomas and Treatments
- Ion channel regulation and function
- Blood Pressure and Hypertension Studies
- Cardiac Fibrosis and Remodeling
- Cardiovascular Health and Disease Prevention
- Acute Ischemic Stroke Management
- Congenital Heart Disease Studies
- Ophthalmology and Visual Impairment Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Intestinal and Peritoneal Adhesions
Shanxi Academy of Medical Sciences
2025
Tianjin Medical University General Hospital
2024
Bristol-Myers Squibb (United States)
2016-2024
Peking Union Medical College Hospital
2023-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2023-2024
National Clinical Research Center for Digestive Diseases
2024
Beijing Anzhen Hospital
2024
Capital Medical University
2024
Beijing Institute of Water
2024
Chinese PLA General Hospital
2024
Background and Purpose- This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes Experience of Patients) used multiple data sources to compare stroke/systemic embolism (SE) major bleeding (MB) among a large number nonvalvular atrial fibrillation patients non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin. Methods- A retrospective observational initiating apixaban, dabigatran, rivaroxaban, warfarin from January 1, 2013,...
In Brief Purpose: To evaluate the occurrence, management, and clinical significance of increases in intraocular pressure (IOP) patients with diabetic macular edema treated dexamethasone intravitreal implant (DEX implant). Methods: Randomized, multicenter, 3-year, Phase III study. Patients (N = 1,048) were randomized to DEX 0.7-mg, 0.35-mg, or sham procedure retreatment allowed at ≥6-month intervals (seven injections maximum). Results: groups, respectively, ≥10-mmHg IOP from baseline occurred...
OBJECTIVES Older adult patients are underrepresented in clinical trials comparing non–vitamin K antagonist oral anticoagulants (NOACs) and warfarin. This subgroup analysis of the ARISTOPHANES study used multiple data sources to compare risk stroke/systemic embolism (SE) major bleeding (MB) among very old with nonvalvular atrial fibrillation (NVAF) prescribed NOACs or DESIGN Retrospective observational study. SETTING The Centers for Medicare & Medicaid Services three US commercial claims...
Dexamethasone intravitreal implant (DEX implant, Ozurdex(®); Allergan, Inc.) is used to treat noninfectious posterior uveitis and macular edema associated with retinal vein occlusion diabetic retinopathy. Two recently published reports of DEX fragmentation shortly after injection have raised concerns about the potential for faster dissolution elevated ocular dexamethasone concentrations. This study compared in vivo release profile pharmacokinetic behavior intact fragmented implants.DEX was...
Cardiac fibroblast (CF) proliferation and transformation into myofibroblasts play important roles in cardiac fibrosis during pathological myocardial remodeling. In this study, we demonstrate that hepatocyte growth factor (HGF), an antifibrotic the process of pulmonary, renal liver fibrosis, is a negative regulator response to transforming factor‑β1 (TGF‑β1). HGF expression levels were significantly reduced CFs following treatment with 5 ng/ml TGF‑β1 for 48 h. The overexpression suppressed...
Abstract In the AMPLIFY clinical trial, apixaban was non-inferior to warfarin plus subcutaneous enoxaparin bridge therapy in treatment of acute venous thromboembolism (VTE) and associated with significantly less bleeding. This study evaluated their comparative effectiveness safety routine practice. A matched-cohort design data from four U.S. private health care claims databases were employed. Study population comprised patients who initiated outpatient versus (plus parenteral anticoagulant...
Background: Micro-aspiration is a significant risk factor for ventilator-associated pneumonia (VAP) in critically ill patients. Recent guidelines have increasingly recommended micro-aspiration prevention strategies; however, the practical application and guidance value of these recommendations still require further evaluation. This study aims to analyze “micro-aspiration prevention” concept control VAP Methods: We conducted randomized controlled trial involving 94 patients at our hospital...
Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few evaluated the effectiveness safety according to its dosage, most contained limited numbers patients prescribed 2.5 mg twice-daily (BID) apixaban. Using pooled data from 4 American claims database sources, baseline characteristics outcomes for 5 BID warfarin were compared. After 1:1 propensity-score matching, 31,827...
This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with obesity prescribed warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) in order to inform clinical decision making. A retrospective observational study was conducted NVAF who were obese initiated apixaban, dabigatran, rivaroxaban, from 1 January 2013-30 September 2015, data pooled CMS Medicare four US commercial claims...
Direct oral anticoagulants (DOACs) are at least as efficacious and safe warfarin among non-valvular atrial fibrillation (NVAF) patients; limited evidence is available regarding NVAF patients with heart failure (HF). US Medicare enrollees HF initiating DOACs (apixaban, rivaroxaban, dabigatran) or were selected. Propensity score matching Cox models used to estimate the risk of stroke/systemic embolism (SE), major bleeding (MB), adverse cardiac events (MACE) comparing versus DOACs. We...
Aims Assess the relationship between New York Heart Association (NYHA) functional class and cardiovascular (CV) outcomes in obstructive hypertrophic cardiomyopathy (HCM).
To address gaps in the data comparing non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin among patients with nonvalvular atrial fibrillation (NVAF) diabetes. A retrospective study was conducted on NVAF diabetes newly initiating apixaban, dabigatran, rivaroxaban, or from January 1, 2013, through September 30, 2015, Medicare US Centers for & Medicaid Services 4 other commercial claims databases. One-to-one propensity score matching completed between NOACs each database, results...
Poor quality of warfarin control (time in therapeutic range [TTR] < 65%) can lead to increased risk adverse events. The objective this study was examine the overall international normalized ratio (INR) and association TTR with clinical outcomes including stroke, major bleeding, all-cause mortality among US users.This retrospective observational cohort utilized Veterans Affairs electronic medical records database (VA EMR). Patients NVAF who newly initiated from 1 January 2005 31 December 2015...
This study describes demographics, thrombotic and bleeding events, mortality, anticoagulant use among hospitalized patients with COVID-19 in the United States. Premier Healthcare Database data were analyzed to identify inpatients a discharge diagnosis for (ICD-10-CM code: U07.1) from April 1, 2020 March 31, 2021, matched historical controls without (inpatients discharged between 2018 2019). Thrombotic [including venous thromboembolism (VTE)] events based on ICD-10-CM codes. Of 546,656...
Background: Atrial fibrillation (AF), which occurs four to six times more frequently in hypertrophic cardiomyopathy (HCM) patients than the general population, is most common persistent arrhythmia and has a substantial therapeutic consequence. In HCM patients, there are currently no discovered signs that could be utilized identify AF. Methods: From 2018 2022, 493 individuals with continuous diagnosis of were examined at Beijing Anzhen Hospital. AF was proven using routine electrocardiography...
To evaluate the relationship between changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) eyes from two clinical trials of dexamethasone intravitreal implant 0.7 mg for macular edema after branch or vein occlusion.Patients with vision loss as a result (≥6-week duration) occlusion were treated single sham. Prospectively defined outcomes included BCVA CRT (as assessed by optical coherence tomography).There was modest but statistically significant negative linear...
Background Glucose fluctuations may be associated with myocardial fibrosis. This study aimed to investigate the underlying mechanisms of glucose fluctuation-related Methods Streptozotocin (STZ)-injected type 1 diabetic rats were randomized five groups: controlled blood (CBG) group, uncontrolled (UBG) fluctuated (FBG) FBG injected 0.9% sodium chloride (NaCl) (FBG + NaCl) and MCC950 MCC950) group. Eight weeks later, left ventricular function was evaluated by echocardiography fibrosis observed...
The aim of the present study was to examine effect metformin on endothelial function in patients with type 2 diabetes mellitus (T2DM). In total, 93 T2DM and dissatisfactory glycemic control were randomly assigned pioglitazone groups changes vascular subsequently observed. Blood sugar levels insulin resistance (IR) index prior treatment lower than those following 12 months treatment. addition, fasting postprandial higher compared obtained (P<0.05). Following treatment, body mass (BMI) group...